Start with the business objective, not the robot — and ask what better, faster data is worth.
Lab automation makes financial sense when it improves your ability to produce valuable data, not only when it cuts labour cost. For a biotech startup, the sharper question is usually whether automation helps the team reach a scientific, fundraising, clinical, or operational milestone faster.
Financial value can come from several places: lower labour cost, higher throughput, better consistency, better data tracking, or experiments that simply aren't practical by hand. The right calculation depends on the organisation — a CRO may care about cost per sample, a diagnostics lab about throughput and reliability, a biotech startup about getting better data before the next milestone.
A pure labour-savings calculation might say automation is only worth it if it replaces several technicians — true in a mature, repetitive process. But in early biotech the bigger value is often speed: if automation lets the same scientists run more experiments and reach better decisions sooner, it can create far more value than it saves in labour.
A useful test: if you could multiply your top scientist's experimental output by five, would that materially change the company's trajectory? If yes, automation is worth evaluating seriously.
Start with the business objective, not the robot. Name the bottleneck that matters most — cost per run, number of experiments, turnaround, consistency, documentation, or proof you can scale the science — then ask whether automation moves it. For the hardware side of the math, see how much lab automation actually costs →
